Clinical Trials

Accrual Status
Limit to SWOG Trials

1027 Results

View
Open
Phase
Accrual
0%
SWOG Clinical Trial Number
S1900K

A Randomized Phase II Study of Tepotinib with or Without Ramucirumab in Participants with MET Exon 14 Skipping Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)
Status Notes
S1900K will open to accrual December 18, 2023, effective 3:00 p.m. EST.
Research Committee(s)
LungMAP
Activated
12-18-2023
ClinicalTrials.gov Registry Number
NCT06031688
Open
Phase
Accrual
0%
SWOG Clinical Trial Number
S2213

A Phase III, Randomized Study of Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone (Dara-VCD) Induction Followed by Autologous Stem Cell Transplant or Dara-VCD Consolidation and Daratumumab Maintenance in Patients with Newly Diagnosed AL Amyloidosis
Status Notes
S2213 is open to patient accrual December 01, 2023, effective 12:00 p.m. Pacific Time.
Research Committee(s)
Myeloma
Activated
12-01-2023
ClinicalTrials.gov Registry Number
06022939
Open
Phase
Accrual
1%
SWOG Clinical Trial Number
S2206

A Randomized trial of neoadjuvant durvalumab plus chemotherapy versus chemotherapy alone for Adults with MammaPrint Ultrahigh (MP2) hormone receptor (HR) positive /Human Epidermal Growth Factor receptor (HER2) negative stage II-III breast cancer
Status Notes
This study is open to patient accrual effective 10/30/23.
Research Committee(s)
Breast Cancer
Symptom Control and Quality of Life
Activated
10-30-2023
ClinicalTrials.gov Registry Number
06058377
Open
Phase
Accrual
2%
SWOG Clinical Trial Number
S2210

S2210, "Targeted Neoadjuvant Treatment for Patients with Localized Prostate Cancer and Germline DNA Repair Deficiency"
Status Notes
Active as of 08/14/2023, 12 PM PST.
Research Committee(s)
Genitourinary Cancer
Activated
08-14-2023
ClinicalTrials.gov Registry Number
NCT05806515
Open
Phase
Accrual
5%
SWOG Clinical Trial Number
S2212

TIL Adapted Neo adjuvant Chemotherapy Optimization in Triple negative breast cancer (SCARLET)
Status Notes
This study is active in SWOG as of July 21, 2023.
Research Committee(s)
Breast Cancer
Activated
07-21-2023
ClinicalTrials.gov Registry Number
NCT05929768
Open
Phase
Accrual
5%
SWOG Clinical Trial Number
S2207

Randomized Phase II Study of the Addition of Targeted Therapeutic Agents to Tafasitamab-Based Therapy in Non-Transplant-Eligible Patients with Relapse/Refractory Large B-Cell Lymphoma
Status Notes
S2207 will open to accrual June 30, 2023, effective 3:00 p.m. EST.
Research Committee(s)
Lymphoma
Activated
06-30-2023
ClinicalTrials.gov Registry Number
05890352
Open
Phase
Accrual
4%
SWOG Clinical Trial Number
S2209

A Phase III Randomized Trial for Newly Diagnosed Multiple Myeloma Patients Considered Frail or Ineligible for Stem Cell Transplant Comparing Frontline Regimen Bortezomib-Lenalidomide-Dexamethasone-Lite (VRd-Lite) with Daratumumab-Lenalidomide-Dexamethasone (DRd) Followed by Len+/-Dara (R+/-D) Maintenance
Status Notes
S2209 is open to patient accrual May 30, 2023, effective 12:00 p.m. Pacific Time.
Research Committee(s)
Myeloma
Activated
05-30-2023
ClinicalTrials.gov Registry Number
05561387
Open
Phase
Accrual
17%
SWOG Clinical Trial Number
S1900G

A Randomized Phase II Study of INC280 (capmatinib) plus Osimertinib with or without Ramucirumab in Participants with EGFR-Mutant, MET-Amplified Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)
Status Notes
S1900G will open to accrual April 3, 2023, effective 3:00 p.m. EST.
Research Committee(s)
LungMAP
Activated
04-03-2023
ClinicalTrials.gov Registry Number
05642572
Open
Phase
Accrual
16%
SWOG Clinical Trial Number
S2205

ICE COMPRESS: Randomized Trial of Limb Cryocompression versus Continuous Compression Versus Low Cyclic Compression for the Prevention of Taxane-Induced Peripheral Neuroropathy
Status Notes
This study is open to patient accrual effective 3/16/23 at 12 p.m. Pacific Time.
Research Committee(s)
Symptom Control and Quality of Life
Activated
03-16-2023
ClinicalTrials.gov Registry Number
05642611
Open
Phase
Accrual
64%
SWOG Clinical Trial Number
S2302

PRAGMATICA - LUNG: A PROSPECTIVE RANDOMIZED STUDY OF RAMUCIRUMAB (LY3009806; NSC 749128) PLUS PEMBROLIZUMAB (MK-3475; NSC 776864) VERSUS STANDARD OF CARE FOR PARTICIPANTS PREVIOUSLY TREATED WITH IMMUNOTHERAPY FOR STAGE IV OR RECURRENT NON-SMALL CELL LUNG CANCER
Status Notes
March 6, 2023: S2302 is open to accrual.

SWOG has partnered with Matthews Media Group (MMG) to help us increase and diversify enrollment to this trial. They may contact your site directly to offer support or ask about potential barriers.
Research Committee(s)
Lung Cancer
Activated
03-06-2023
ClinicalTrials.gov Registry Number
05633602
Open
Phase
Accrual
3%
SWOG Clinical Trial Number
EAY191-S3

Phase 2 Study of Paclitaxel + Ipatasertib in Taxane-Refractory Patients with AKT-Altered Advanced Non-Breast Solid Tumors
Status Notes
This study is open to participant enrollment effective 12pm PT on 3/6/2023.
Research Committee(s)
comboMATCH
Immunomolecular Therapeutics
Activated
03-06-2023
ClinicalTrials.gov Registry Number
05554380
Open
Phase
Accrual
10%
SWOG Clinical Trial Number
S2114

A Randomized Phase II trial of consolidation therapy following CD19 CAR T-cell treatment for Relapsed/Refractory Diffuse Large B-cell Lymphoma or Grade IIIB Follicular Lymphoma
Status Notes
Activated: Effective Thursday, February 23, 2023 at 12:00 PM Pacific Time
Research Committee(s)
Lymphoma
Activated
02-23-2023
ClinicalTrials.gov Registry Number
05633615
Open
Phase
Accrual
51%
SWOG Clinical Trial Number
S2010

A Randomized Phase III Trial Comparing Active Symptom Monitoring Plus Patient Education Versus Patient Education Alone To Improve Persistence with Endocrine Therapy in Young Women With Stage I-III Breast Cancer (ASPEN)
Status Notes
This study is open to participant accrual, effective January 17, 2023, at 12:00 p.m. Pacific Time.
Research Committee(s)
Symptom Control and Quality of Life
Activated
01-17-2023
Open
Phase
Accrual
15%
SWOG Clinical Trial Number
S2101

Biomarker Stratified CaboZantinib and NivOlumab (BiCaZO) - A phase II study of combining cabozantinib and nivolumab in patients with advanced solid tumors stratified by tumor biomarkers
Status Notes
Activation: This study is reopened to accrual effective January 16th, 2024 at 12PM PST.
Research Committee(s)
iMATCH
Head and Neck Cancer
Melanoma
Early Therapeutics & Rare Cancers
Immunomolecular Therapeutics
Activated
10-14-2022
ClinicalTrials.gov Registry Number
NCT 05136196
Open
Phase
Accrual
8%
SWOG Clinical Trial Number
S2200

S2200, A Phase II Randomized Trial of Cabozantinib with or Without Atezolizumab in Patients with Advanced Papillary Renal Cell Carcinoma: PAPMET2
Status Notes
Active effective 09/19/2022
Research Committee(s)
Genitourinary Cancer
Activated
09-19-2022
ClinicalTrials.gov Registry Number
NCT05411081
Open
Phase
Accrual
81%
SWOG Clinical Trial Number
S2108CD

A Cluster Randomized Trial Comparing an Educationally Enhanced Genomic Tumor Board (eGTB) Intervention to Usual Practice to Increase Evidence-Based Genome Informed Therapy
Research Committee(s)
Cancer Care Delivery
Activated
08-22-2022
ClinicalTrials.gov Registry Number
NCT # 05455606
Closed
Phase
Accrual
0%
SWOG Clinical Trial Number
S1900F

A Randomized Phase II Study of Carboplatin and Pemetrexed with or without Selpercatinib (LY3527723) in Participants with Non-Squamous RET Fusion-Positive Stage IV Non-Small Cell Lung Cancer and Progression of Disease on Prior RET Directed Therapy (Lung-MAP Sub-Study)
Status Notes
Closed 6/27/2023
Research Committee(s)
LungMAP
Activated
07-25-2022
Closed
06-27-2023
ClinicalTrials.gov Registry Number
05364645
Open
Phase
Accrual
73%
SWOG Clinical Trial Number
S2107

Randomized Phase II Trial of Encorafenib and Cetuximab with or Without Nivolumab (NSC #748726) for Patients with Previously Treated, Microsatellite Stable, BRAFV600E Metastatic and/or Unresectable Colorectal Cancer
Status Notes
Activation Date: 06/06/2022
Research Committee(s)
Gastrointestinal Cancer
Activated
06-06-2022
ClinicalTrials.gov Registry Number
NCT05308446
Closed
Phase
Accrual
17%
SWOG Clinical Trial Number
S1800D

A Phase II/III Study of N-803 (ALT-803) plus Pembrolizumab versus Standard of Care in Participants with Stage IV or Recurrent Non-Small Cell Lung Cancer Previously Treated with Anti-PD-1 or Anti-PD-L1 Therapy (Lung-MAP Non-Match Sub-Study)
Status Notes
S1800D is permanently closed to accrual, effective March 10, 2023. This is an FDA registration study. There will be additional centralized and on-site monitoring conducted in addition to routine audits. Sites must also maintain a study specific Trial Master File for this study (https://swog.org/Visitors/QA/Index.asp).
Research Committee(s)
LungMAP
Lung Cancer
Activated
02-15-2022
Closed
03-10-2023
Open
Phase
Accrual
23%
SWOG Clinical Trial Number
S2012

Randomized Phase II/III Trial of First Line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with Poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)
Status Notes
Activation: Effective December 02, 2021 at 2:00 p.m. Eastern.
Research Committee(s)
Early Therapeutics & Rare Cancers
Activated
12-02-2021
ClinicalTrials.gov Registry Number
NCT05058651